Current Allergy and Asthma Reports

, Volume 6, Issue 3, pp 232-238

First online:

RETRACTED ARTICLE: Treating allergic rhinitis in pregnancy

  • Vincent Piette
  • , Jean-Pierre Daures
  • , Pascal DemolyAffiliated withExploration des Allergies-Maladies Respiratoires—INSERM U454, Höpital Arnaud de Villeneuve, University Hospital of Montpellier Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Numerous pregnant women suffer from allergic rhinitis, and particular attention is required when prescribing drugs to these patients. In addition, physiologic changes associated with pregnancy could affect the upper airways. Evidence-based guidelines on the management of allergic rhinitis have been published. Medication can be prescribed during pregnancy when the apparent benefit of the drug is greater than the apparent risk. Usually, there is at least one "safe" drug from each major class used to control symptoms. All glucocorticosteroids are teratogenic in animals but, when the indication is clear (for diseases possibly associated, such as severe asthma exacerbation), the benefit of the drug is far greater than the risk. Inhaled glucocorticosteroids (eg, beclomethasone or budesonide) have not been incriminated as teratogens in humans and are used by pregnant women who have asthma. A few H1-antihistamines can safely be used as well. Most oral decongestants (except pseudoephedrine) are teratogenic in animals. There are no such data available for intranasal decongestants. Finally, pregnancy is not considered to be a contraindication for the continuation of immunotherapy.